Omaha, Nebraska
Phase 3 cancer trials in Omaha, NE
57 Phase 3 cancer studies are recruiting participants at sites in Omaha as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Omaha at a glance
- 57 studies are recruiting at a site in Omaha.
- By phase: Phase 2/3 (7), Phase 3 (50).
- By sponsor: industry (34), university, hospital or other (20), government (3).
- By research area: Breast Cancer (14), Lung Cancer (13), Prostate Cancer (12), Lymphoma (9), Pancreatic Cancer (6), Melanoma (3).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Omaha
Basic details from each study's public record (the 30 most recently updated of 57). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
- Registry record
- NCT07391774 · updated
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Relay Therapeutics, Inc.
- Study site
- Nebraska Cancer Specialists
- Registry record
- NCT06982521 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study sites
- Nebraska Methodist Hospital (change from Chi Health Bergan Mercy) · Oncology Hematology West - Methodist
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
- Registry record
- NCT05879926 · updated
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Nebraska Cancer Specialists
- Registry record
- NCT06790693 · updated
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists
- Registry record
- NCT07173751 · updated
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Nebraska Cancer Specialists
- Registry record
- NCT07492641 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Omaha, NE on ClinicalTrials.gov.
Lung cancer studies recruiting in Omaha
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists
- Registry record
- NCT07063745 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC · Nebraska Medicine-Village Pointe · Nebraska Methodist Hospital
- Registry record
- NCT04267848 · updated
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists · Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Methodist · Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan
- Registry record
- NCT06758401 · updated
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- University of Nebraska Medical Center
- Registry record
- NCT07472517 · updated
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Nebraska Medicine · Nebraska Medicine - Village Pointe · University Of Nebraska Medical Center
- Registry record
- NCT07144280 · updated
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Mirati Therapeutics Inc.
- Study site
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy
- Registry record
- NCT04613596 · updated
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT06357533 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Omaha, NE on ClinicalTrials.gov.
Prostate cancer studies recruiting in Omaha
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Alegent Health Bergan Mercy Medical Center
- Registry record
- NCT04423211 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095)
- Registry record
- NCT06136624 · updated
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- NRG Oncology
- Study sites
- Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
- Registry record
- NCT05946213 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Omaha, NE on ClinicalTrials.gov.
Melanoma studies recruiting in Omaha
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
- Registry record
- NCT07068074 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists
- Registry record
- NCT06246916 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- University of Nebraska Medical Center
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Omaha, NE on ClinicalTrials.gov.
Lymphoma studies recruiting in Omaha
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital and Medical Center of Omaha · Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
- Registry record
- NCT05675410 · updated
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
- Registry record
- NCT06846671 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- University of Nebraska Medical Center (UNMC)
- Registry record
- NCT07188558 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
- Registry record
- NCT03150693 · updated
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177)
- Registry record
- NCT05139017 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
- Registry record
- NCT05976763 · updated
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Nebraska Cancer Specialists
- Registry record
- NCT06742996 · updated
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- University of Nebraska Medical Center
- Registry record
- NCT06943872 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Omaha, NE on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Omaha
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study site
- University of Nebraska Medical Center
- Registry record
- NCT07562152 · updated
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- University of Nebraska Medical Center
- Registry record
- NCT06943755 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Omaha, NE on ClinicalTrials.gov.
Ask about studies near Omaha
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections